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The maintenance and regulation of continuously renewing 
tissues is ultimately controlled at the level of stem-cell prolif-
eration. We have recently identified a reversible inhibitor of 
hemopoietic stem-cell proliferation (stem-cell inhibitor 
[SCI]), which is identical to the macrophage inflammatory 
protein, MIP-10', a 69 - amino-acid heparin-binding cyto-
kine. To test the cell/tissue specificity of the inhibition of 
proliferation by SCI/MIP-10', we have investigated its activ .... 
ity on epidermal keratinocytes, the principal cell type of an-
other continuously renewing tissue. Here we show that SCI/ 
MIP-10' inhibits the proliferation of epidermal keratinocytes 
e have recently identified a reversible inhibi-
tor of hemopoietic stem-cell (colony-forming 
unit spleen) proliferation [1] and have shown 
it to be identical to a previously described cy-
tokine, macrophage inflammatory protein-
10' (MIP-1a), a member of a large and expanding family of related 
pep tides [2]. The proposed fundamental role for MIP-la in the 
hemopoietic system has prompted us to investigate the possibility 
that MIP-la may be capable of acting as an inhibitor of primitive 
cells in other rapidly proliferating tissues. 
Clonogenic cu ltured epidermal keratinocytes, like hemopoietic 
colony-forming unit spleen cells [3], display heterogeneity in their 
self-renewal capacity [4] and can reconstitute their tissue of origin in 
syngeneic or immunosuppressed animals [5,6], making them an 
excellent target cell to determine the tissue specificity ofSCI/MIP-
10' as an inhibitor of proliferation. 
Interfollicular mouse epidermis is organized into columnar epi-
dermal pro liferative units, which are comprised of a stack of matur-
ing cells superimposed on a group of proliferating basal keratino-
cytes. When viewed from above, the basal cells of the epidermal 
proliferative units are organized into an outer ring of six or seven 
cells and an inner group of three or four cells, one of which is the 
putative stem keratinocyte of the unit, and another of which is an 
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ill vitro and that the MIP-10' mRNA is present in epidermal 
Langerhans cells but not in keratinocytes. This suggests an 
important growth regulatory function for SCI/MIP-10' in 
keratopoiesis, as well as hemopoiesis, and may also indicate a 
novel role for the epidermal Langerhans cell. As SCI/MIP-
10' can inhibit the proliferation of embryologically distinct 
precursor cells, this raises the possibility that it may also 
function in a number of other tissues. Keywords: Stem-cell 
inhibitor, macrophage inflammatory protein-la, hemato-
poietic stem-cell proliferation. ] Invest Dermatol 101.' 113-
117,1993 
epidermal Langerhans cell (see [7] for review). The two most cen-
trally placed basal keratinocytes (one of which is a stem cell) cycle 
more slowly than the rest [7] and coincidentally are in close physical 
contact with the epidermal Langerhans cell [7], an observation that 
has prompted the suggestion that the epidermal Langerhans cell 
may regulate the keratinocyte stem cell [8 J. However, no biologic or 
molecular evidence to support this idea has been forthcoming , 
largely due to the difficulties previously encountered in the efficient 
isolation of epidermal Langerhans cells. In a paper recently pub-
lished, Heufler et al [9] describe the detection of SCIjMIP-la tran-
scripts in highly purified preparations of epidermal Langerhans cells 
by the polymerase chain reaction. We have extended these observa-
tions to show that the epidermal Langerhans cell is the source of 
SCI/MIP-1a in epidermis and that SCI/MIP-1a is a potent inhibi-
tor of murine as well as human keratinocyte proliferation. 
MATERIALS AND METHODS 
Preparation of the SCI/MIP-la and MIP-tp Proteins Recombinant 
SCI/MIP-la and MIP-1P were partially purified from the conditioned me-
dium of COS monkey kidney cells transfected with the appropriate pXM-
cDNA construct by heparin-affinity chromatography [1]. The MIP proteins 
were eluted by 0.5 M NaCljO.02 M Tris pH 7.6 and desa lted into keratino-
cyte basal medium (KBM; Clonetics Inc., San Diego, CAl. The purities of 
the MIP-la and MIP-1P pep tides were 90-95% in these preparations, 
which were used for the proliferation inhibition experiments unless other-
wise stated . SCI/MIP-la was purified to homogeneity from the above 
material by reverse-phase HPLC for use in some experiments. A high-per-
formance liquid chromatography (HPLC) profile of COS cell-derived SCI/ 
MIP-la is shown in Fig 1. The purities and amounts of the macrophage 
inflammatory proteins were estimated from silver-stained gels and the con-
centrations given in the figures were calculated assuming a molecular weight 
of 100 kd for SCI/MIP-la and MIP-1P, as the macrophage inflammatory 
proteins form aggregates of approximately ten molecules [1]. 
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Figure 1. High-performance liquid chromatography profi le of COS cell -
derived SCI/MIP-la after heparin column enrichment. Five milli liters of 
heparin-bindin g fraction of MIP-la COs supernatant was loaded in 0.1 % 
w /v trifluoroacetic acid onto a C4 reverse-phase column and the MIP-la 
diluted with 30 -40% acetonitrile. Protein elution was followed by moni-
toring absorption at 280 nm. The position of MIP- la is indicated and the 
major contaminants are marked by arrows. 
Cell Culture Human epidermal keratinocytes were obtained by trypsin 
treatment of human fo reskin (Line R) or extraconchal skin (Line HEK-79) as 
described previously [10] and cultured with lethally irradiated Swiss 3T3 
cells as described [10,11] . After around 20 population doublings, the cells 
were cryopreserved. For experiments the cel ls were thawed, washed twice in 
calcium- and magnesium-free phosphate-buffered saJine before seeding in 
serum-free keratinocyte basal medium contain ing 0.4% vol/vol bovine pi-
tuitary extract,S J1g/ml insulin, 0.5 J1g/ml hydrocortisone, and 5 ng/ml 
epidermal growth factor (KGM, keratinocyte basal medium plus additives, 
all reagents from Clonetics) . KGM is similar to the previously described 
MCDB 153 medium [1 2]. Mouse epidermal keratinocytes were prepared in 
a similar way to the human epidermal keratinocytes, as described [10], and 
were plated in KGM that contained 0.03 mM calcium (Clonetics) instead of 
the 0.15 mM calcium used to culture human keratinocytes. For mRNA 
preparation, both human and mouse keratinocytes were cultured in the 
appropriate KGM already modified by Clonetics to improve high-density 
proliferation and viability [1 3]. Dermal fibroblasts of both species were 
prepared by collagenase (Sigma Type III; Poole, Dorset, UK) digestion of 
th e dermis remaining after keratinocyte isolation [10] and were cultu red in 
Dulbecco's modification of Eagle's medium containing 15% vol/vol bovine 
serum (both from Life Sciences Technology, Paisley, Scorland, UK). The 
melanoma lines were all cultured in Dulbecco's medium containing 10% 
vol/vol fe tal bovine serum and RAW 264.7 murine macrophages [14] and 
Swiss 3T3 cells [15] were cu ltured as described previously. 
Plating Efficiency Assays, Clonogenic Assays, and Growth Curves 
Human and mouse keratinocytes were seeded at 104 cells per 35-mm culture 
well in sextuplet in the appropriate KGM with or without MIP-la or 
MIP- l/l at the stated dose. After 24 h, half the wells were rinsed twice in 
calcium- and magnesium-free phosphate-buffered saline, fixed in buffered 
10% vol/vol formalin in calcium- and magnesium-free phosphate-buffered 
sa line pH 7.4, and the number of attached cel ls counted by examination 
under a phase-contrast microscope. At least 20 fields were counted per well 
and the total number of cells attached per well calculated by multiplying the 
average number of attached cells per field by the area of the 35-mm well/the 
area of the microscope field. Colonies were similarly fixed after 5 d and 
scored (if they contained eight cel ls or more) under a low-power microscope. 
For growth curves the human keratinocytes were seeded at 5 X 104 cells per 
35-mm culture dish in KGM with or without MIP-1a, and at the indicated 
times were disaggregated using trypsin (Worthington crystalline; Lome 
Biochemicals Ltd., Reading, UK) and EDTA (BDH Chemicals; Poole) as 
described [1 0] before counting in a hemocytometer. 
To assess the reversibil ity of the effects of SCI/MIP-la human keratino-
cytes were seeded in KGM at 7 X 104 - 1.4 X 105 cells per 35-mm dish to 
ensure that treated and control ce ll cultures had a similar density at the point 
when they were trypsinised and replated, as ce ll density greatly affects the 
subsequent cloning efficiency of keratinocytes upon transfer [13] . After 
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48 h, the medium was changed to either control KGM or the same medium 
containing SCI/MIP-1a. After a further 48 h, the cultures were trypsinized 
as described [10], washed, and then replated at 3 X 10l/35-mm diameter 
petri dish. The colonies were then fixed and scored as stated above. 
SCI/MIP-la Neutralization Experiments Recombinant COS cell-
derived mouse SCI/ MIP-l a (90 - 95% pure) in KBM prepared as described 
above was incubated in the presence of a goat polyclonal neutralizing anti-
body to mouse SCI/MIP-la (obtained from R&D Systems, Minneapolis, 
MN) at 37"C for 90 min. This antibody, which is specific for SCI/MIP-la 
on Western blots, was used at concentrations sufficient to give a final dilu-
tion of 1 : 50 in the c1onogenic assays. SCI/MIP-1a, control samples, and the 
antibody control samples were also incubated as described above. The SCI! 
MIP-la concentration used in these experiments was 0.15 nM and the 
c1onogenic assay was performed as described above. 
Preparation of the Epidermal Langerhans Cells Epidermal Langer-
bans cells (more tban 98% pure) were prepared from 200 trypsinized Balb/c 
mouse ears by panning exactly as described [1 6]. Briefly, keratinocytes and 
other contaminating cells were lysed using Thy-l antibody and comple-
ment, followed by panning using the monoclonal antibody anti-Ekd and 
elution using rat 1 gG. 
Northern Blotting RNA was prepared by direct lysis of all cell types in 
the Petri dishes in buffer containing guanadinium [17] and the total [17] and 
polyadenylated mRNA isolated by conventional techniques [18]. 
The C I0 lymphocyte [1 9] polyadenylated mRNA was a generous gift 
from Dr. Deb Donaldson (Genetics Institute, Cambridge, MA) and was used 
as a positive control for human SCI/MIP-la. 
RNA was resolved by electrophoresis through 1 % agarose formaldehyde 
gels. Loading and RNA integrity was assessed by ethidium bromide staining 
of the agarose gels before transfer to a Biotrans nylon membrane. l2P-labeled 
RNA probes were prepared from coding sequence cDNAs of SCI/MIP-la 
(mouse samples) or LD78 (human SCI/ MIP-1a, see [20] , human samples) 
cloned into pBluescript II SK (+) (pSK Stratagene Cloning Systems, [21 ]). 
Hybridization was carried out overnight at 65°C in buffer containing 50% 
vol/vol formamide , 5 X sodium citrate/sodium chloride buffer (SSe) 
20 mM sodium phosphate buffer (pH 6.5) 1 X Denhardt's solution, 10% 
dextran sulphate, 0.1% sodium dodecylsulfate, and 1 mg/ml denatured 
salmon sperm DNA. After hybridization, the membranes were washed in 
0.1 X SSC, 0.1% sodium dodecylsulfate at 65 °C for 2 h and auto radio-
graphed. 
RESULTS 
SCI/MIP-1a Inhibits HEK and MEK Proliferation In clon-
ogenic assays, partially purified recombinant mouse SCI/MIP-la 
(95 % pure) completely inhibited human keratinocytes co lony for-
m ation (Fig 2a). Half maximal inhibition was observed at between 
50 and 100 pM and complete inhibition at approximately 500 pM. 
The heparin-binding proteins present in untransfected COS cell-
conditioned medium were without inhibitory activity at protein 
concentrations equivalent to 5 nM SCI/MIP-la. The inhibitory 
effects of SCI/MIP-la were observed with human keratinocytes 
isolated from two different donors (Fig 2c) and also with murine 
epidermal keratinocytes (data not shown). The results with human 
keratinocytes were not affected by culturing them in KGM contain-
ing 2 mM calcium [12) or in Dulbecco's m edium (1.8 mM calcium) 
with irradiated 3T3 feeder layers [10,11) (data not shown). In the 
presence of 3T3 feeders , the human keratinocyte colony-forming 
cells are known to be heterogeneous with respect to their self-re-
newal potential [4], so the absence of a resistant clonogenic kerati.-
nocyte population contrasts with the action of SCI/MIP-la in the 
hemopoietic system, where the inhibitory activity is restricted to 
the stem-cell compartment (colony-forming unit spleen) of the re-
generating hierarchy. 
The closely related mo use MIP-l/l cytokine [22) is m ade in only 
sm all amounts by epidermal Langerhans cells [9) and w as inactive in 
both hemopoietic [1) and epidermal (Fig 2a) clonogenic assays at 
equivalent concentrations to SCI!MIP-la. However, MIP-l/l w as 
ac tive in human keratinocyte clonogenic assays , at 80-100 times 
higher concentrations (Fi g 2a). It will be of interest to examine 
these higher concentrations in the hemopoietic clonogenic assays. 
Neither MIP-la or MIP-l/l affected keratinocyte attachment at any 
dose studied (Fig 2b). To demonstrate th at the inhibitory effect of 
the SCI/MIP-la preparations was due to the SCI/MIP-la protein, 
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Figure 2. T he effects ofSCI/ MIP-la on the cloning efficiency (a), plating 
efficiency (b), and proliferation (c) of human epidermal keratinocytes. The 
cloning and plating efficiencies were evaluated microscopically after incu-
bation in 2 ml ofKGM at 37"C for 5 d, respectively, as detailed in Ma terials 
alld Methods. The proliferation of the keratinocytes was determined from the 
cell yields at each time point as stated ea.rlier (Ma terials mId Methods). T he 
figures given are the results of3- 4 experiments ± SEM (a,b) or the result of 
a single experiment (c) . The control cloning efficiency in (a) was 5.8 ± 
2.0% (±SEM). The control plating efficiency in (b) was 40.5 ± 13.6% 
(±SEM). a,b) e, MIP-la; ., MIP-tp. c) 0, normal diploid HEK line R 
control; e, normal diploid HEK line R 1.0 nm MIP-a; D, normal diploid 
HEK line HEK-79 control;., normal diploid HEK line HEK-79 1.0 nM 
MIP-a. 
samples of COS cell-derived mouse SCI/MIP-IO' were preincu-
bated with an anti-mouse MIP-IO' neutralizing antibody (R & D 
Systems). The results (Fig 3) clearly show that the antiserum com-
pletely reverses the effects of a 0.15 nM dose of SCI/MIP-IO' but 
does not have a stimulatory effect on human epidermal keratinocyte 
cultures that received no SCI/MIP-IO', suggesting that little or no 
SCI/MIP-IO' was produced by the keratinocytes (see also Fig 4b). 
Despite this clear evidence that SCI/MIP-1O' is essential for the 
inhibitory effect of the COS cell-derived recombinant SCI/MIP-
1O' on keratinocyte proliferation, we have found that the growth 
inhibitory effect of completely pure bacterially produced SCI/ 
MIP-1O' is very weak (half maximal dose> 10 nM). Taken to-
gether, these results still suggest that SCI/MIP-!O' is capable of 
inhibiting the clonogenic proliferation of epidermal cells. How-
ever, we believe that activation ofSCI/MIP-! O' requires a structural 
modification or that an accessory protein is required to allow it to 
function as a keratinocyte proliferation inhibitor. We have purified 
SCI/MIP-1O' from the partially purified preparation used in these 
studies and have shown it to be inactive in the epidermal assays. 
These preparations and those produced from bacteria are active 
however, in the ill vitro CFU-A hemopoietic clonogenic assay, 
which contains macrophages, but not in assays using pure hemopoi-
etic stem cell lines such as FDCP-mix. This suggests that macro-
phages are a source of an accessory factor or that they can modify the 
SCI/MIP-!O' in some way. This is in agreement with the observa-
tion that preparations of partially pure SCI/MIP-!O' or macrophage 
inflammatory protein prepared from macrophages are active as in-
hibitors of keratinocyte proliferation (G. Graham and E.K. Parkin-
son, unpublished data). Bacterially expressed SCI/ MIP-!O' does not 
have an increased effect when a) combined with the heparin-puri-
fied proteins isolated from non-transfected COS cells or b) com-
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Figure 3. Neutra lization of the inhibitory effects of SCI/ MIP-la on 
human epidermal keratinocyte proliferation . T he effects of the SCI/ MIP-
l a neutralizing antibody on SCI/ MIP-Ia- mediated inhibition of human 
epidermal keratinocyte cloning efficiency was evaluated microscopica lly as 
detailed in Fig 2a and in Materials mId Methods. T he dose of SCI/MIP-la was 
0.15 nM. The figures given arc the results of three experiments ± SEM. The 
control cloning efficiency was 8.0 ± 0 .2% (±SEM). 
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Figure 4. Northern Blot analysis of mouse (a) and human (b) skin cell 
RNA. (a) RAW, RAW 264.7 total RNA (5 pg); 3T3, Swiss 3T3 total RNA 
(10 pg); ELC, epidermal Langerhans cell total RNA (5 pg); MEK, mouse 
epidermal keratinocyte total RNA (20 Ilg); MDF, mouse dermal fibroblasts 
(third passage) total RNA (20 pg); B16, mouse melanoma line B16 total 
RNA (20 Ilg). (b) CIO, CIO polyadenylated mRNA (2 pg); HEK, human 
epidermal keratinocytes total RN A (20 pg); HEK Poly A, human epidermal 
keratinocyte polyadenylated RNA (2 pg); HDF, human dermal fibroblasts 
(third-passage) total RNA (20 Ilg); B0008, human melanoma line B0008 
total RNA (20 pg); BOOIO, human melanoma line BOOIO total RNA 
(20 pg). Arrows, position of the c.700-bp mouse SCI/MIP-la (a) or LD78 
(human SCI/MIP-la, b) transcripts. 
bined with the proteins furified away from SCI!MIP-la during 
HPLC, suggesting that i an accessory factor is responsible for the 
bioactivity of SCI!MIP-la it must be either labile or need to be 
secreted together with the SCI!MIP-la in order to function. The 
first of these possibilities seems more likely, because bacterially ex-
pressed SCI!MIP-la can function as an inhibitor of hemopoietic 
stem-cell proliferation when added to the CFU-A assay (data not 
shown). We have also tested a number of candidate accessory fac-
tors. Neither soluble heparin (an analogue of heparan sulphate) nor 
soluble chondroitin sulphate had any effect on the activity of puri-
fied recombinant MIP-la, suggesting that simple proteoglycan 
presentation will not reconstitute inhibitory activity. We have also 
shown that MIP-la will not synergize with suboptimal amounts of 
transforming growth factor P, a well characterized inhibitor of 
clonogenic epidermal cells. However, at the moment we cannot 
rule out the possibility that structural modifications are required to 
activate SCI!MIP-la as a proliferation inhibitor. 
The Effects ofSCI!MIP.la Are Fully Reversible As human 
keratinocyte proliferation and colony formation if unaffected by a 
48-h pretreatment with SCI!MIP-la, the inhibitory effect is re-
versible and is not a consequence of cytotoxicity or terminalmatu-
ration (Table I). Furthermore, this pretreatment did not decrease 
keratinocyte sensitivity to the inhibitor, demonstrating that SCI! 
MIP-la - resistant cells were not being selected. 
Epidermal Langerhans Cells Are a Source ofSCI! MIP-la in 
the Epidermis To explore the relevance of our ill vitro observa-
tions on keratopoiesis ill vivo, the availability ofSCI!MIP-la gene 
transcripts for translation in cells comprising the skin was exam-
ined. SCI!MIP-la mRN A was undetectable in either mouse epi-
dermal keratinocytes (Fig 4a), human epidermal keratinocytes (Fig 
4b), cultured melanoma cells, or fibroblasts (Fig 4a,b). Furthermore, 
SCI/MIP-1a transcripts were not detectable in polyadenylated 
human keratinocyte mRNA by Northern blotting (Fig 4b). In add i-
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tion, we were unable to detect SCI!MIP-1 a transcripts in human 
keratinocytes, melanoma cells, or fibroblasts by the polymerase 
chain reaction using actin as a control for RNA integrity (data not 
shown). 
Given the hemopoietic origin of epidermal Langerhans cells [23] 
and their close spatial relationship to the keratinocyte stem cells of 
the epidermal proliferative unit [7 ,8], we determined whether epi-
dermal Langerhans cells were a potential source ofSCI!MIP-la in 
the epidermis. Northern blot analysis of epidermal Langerhan's 
cells total cell RNA (Fig 4a) clearly shows that this is the case, 
confirming the results of Heufler et al [9] . 
DISCUSSION 
In this paper we have described data that characterize SCI!MIP-la 
as a non-toxic reversible inhibitor of keratinocyte proliferation. 
Many such inhibitors of keratinocyte proliferation have been de-
scribed before, but, without exception, all have been shown to be 
synthesized by the keratinocytes themsel ves. For example, trans-
forming growth factor PI is also a potent inhibitor of basal keratino-
cyte proliferation [24]. However, unlike transforming growth fac-
tor P, which is produced by suprabasal keratinocytes [24,25]' and 
other keratinocyte proliferation inhibitors (see, for example, 
[26,27]), SCI!MIP-la is not expressed by epidermal keratinocytes 
or transformed melanoma cells, but is apparently expressed by epi-
dermal Langerhans cells (Fig 4, [9]). We have not conclusively ruled 
out expression of SCI!MIP-la by normal melanocytes but these 
cel ls are not very abundant in adult epidermis [7] . Previously, SCI! 
MIP-1a gene expression had only been reported in macrophages 
[2] , T cells [20], and mast cells [28] and because very few of these cell 
types are normally present in the epidermis [29]' these data suggest 
that the epidermal Langer han's cells are the major source of SCI! 
MIP-la in this tissue and that SCI!MIP-la has a novel role, distinct 
from transforming growth factor P in keratinocyte growth control. 
There was no evidence for any specificity of SCI!MIP-la within 
the keratinocyte lineage, in contrast to the well documented situa-
tion in the hemopoietic system; SCI!MIP-la was capable of inhib-
iting all c1onogenic keratinocytes (Fig 2a). However, while SCI! 
MIP-la would most likely be capable of inhibiting all the basal 
keratinocytes of the epidermal proliferative unit, its action at the site 
of the epidermal Langerhans cell would readily be explained by its 
local sequestration by epidermal heparan sulphate [30,31]' as SCI! 
MIP-1a binds strongly to the chemically related heparin [2]. Hepa-
ran sulphate has been shown to bind some cytokines in a biologi-
cally active form [32] and in other instances such interactions have 
been shown to be essential for cytokine function [33]. 
Our results also suggest a potential role for SCI!MIP-la as a 
contributing factor in the process of skin wound repair and inflam-
mation, during which tissue infiltration by macrophages and lym-
phocytes may produce a local gradient of stem-cell inhibitor. This 
hypothesis may also help explain the reduction in keratinocyte pro-
liferation observed at the edges of wounds. 
The results described above strongly suggest an important role for 
SCI!MIP-1a in normal skin physiology and wound repair and may 
also indicate a novel role for the epidermal Langerhans cell in the 
environmental maintenance of the keratinocyte stem-cell pheno-
type. The characterization of SCI!MIP-1a as an inhibitor ofkerati-
Table I. Reversibility of the Inhibitory Effects of SCI!MIP-
1a on Human Epidermal Keratinocyte Proliferation' 
Treatment 
Control KGM 
2.5 nM 
SCI/MIP-la 
D ensity / cm2 
when 
Replated X 10- 3 
6.0 ± 2.4 
7.5 ± 2.0 
% C loning 
Efficiency 
11.2 ± 2.4 
11.4 ± 2.8 
Relative 
Colony-Forming 
Efficiency 
100 
100.2 ± 13.4 
, The cloning efficiency was evaluated microscopically as detailed in Materials a"d 
M ethods and in Fig 2a. The results arc the average of (our expcrilncnts ± SEM. 
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nocyte proliferation suggests that it may influence a wider range of 
normal clonogenic cell types than was first realized. 
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